U.S. mass tort: Ozempic & GLP-1 litigati… | DrugsMonitor.com

Ozempic & GLP-1 litigation —primer on claims in play, court posture, key deadlines, and a confidential attorney review—not legal advice.

semaglutide, tirzepatide, Wegovy, Mounjaro, Rybelsus, gastroparesis, intestinal obstruction

This page summarizes publicly discussed themes in litigation involving GLP-1 receptor agonists—medications widely prescribed for type 2 diabetes and, in some forms, chronic weight management. Coordinated federal cases have focused on severe gastrointestinal complications and related injuries alleged by some patients after use.

Products and reported injury patterns

GLP-1 agonists—including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda)—mimic a hormone that affects insulin and appetite. They have helped many patients meet glycemic or weight goals, but a subset of users have reported debilitating stomach and intestinal problems.

Litigation pleadings and media coverage have highlighted diagnoses such as severe gastroparesis (stomach paralysis), ileus or bowel obstruction, persistent vomiting, and emergency interventions. Allegations in civil complaints often include failure to warn and related product-liability theories. Regulatory agencies have issued or updated safety communications as post-marketing data accumulated; regulatory action is separate from private lawsuits.